ImmunityBio, Inc. (IBRX)
NASDAQ: IBRX · IEX Real-Time Price · USD
8.20
-0.79 (-8.79%)
Apr 30, 2024, 2:34 PM EDT - Market open
ImmunityBio Employees
ImmunityBio had 628 employees on December 31, 2023. The number of employees decreased by 97 or -13.38% compared to the previous year.
Employees
628
Change (1Y)
-97
Growth (1Y)
-13.38%
Revenue / Employee
$990
Profits / Employee
-$928,656
Market Cap
5.53B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 628 | -97 | -13.38% |
Dec 31, 2022 | 725 | 138 | 23.51% |
Dec 31, 2021 | 587 | 416 | 243.27% |
Dec 31, 2020 | 171 | 23 | 15.54% |
Dec 31, 2019 | 148 | -13 | -8.07% |
Dec 31, 2018 | 161 | 22 | 15.83% |
Dec 31, 2017 | 139 | 57 | 69.51% |
Dec 31, 2016 | 82 | 51 | 164.52% |
Dec 31, 2015 | 31 | 16 | 106.67% |
Dec 31, 2014 | 15 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
R1 RCM | 30,000 |
Grifols | 23,737 |
Bausch + Lomb | 13,300 |
Organon & Co. | 10,000 |
Option Care Health | 7,802 |
Haemonetics | 3,034 |
Glaukos | 907 |
BridgeBio Pharma | 550 |
IBRX News
- 6 hours ago - ImmunityBio Executive Chairman Dr. Patrick Soon-Shiong to Discuss ANKTIVA® Approval in Fireside Chat at the Annual Conference of the American Urological Association - Business Wire
- 1 day ago - What's going on with the ImmunityBio (IBRX) stock price? - Invezz
- 5 days ago - ImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell Lung Cancer; Meeting Scheduled with FDA to Discuss Registration Path for ANKTIVA in Lung Cancer - Business Wire
- 7 days ago - Here's why ImmunityBio (IBRX) stock price surged and what next - Invezz
- 7 days ago - ImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer - Business Wire
- 7 days ago - U.S. FDA approves ImmunityBio's bladder cancer therapy - Reuters
- 7 weeks ago - NIAID-Sponsored Study Shows N-803 Combined with Neutralizing Antibodies Could Lead to Sustained HIV Viral Control After Discontinuation of Antiretroviral Therapy - Business Wire
- 2 months ago - N-803 Combined with Natural Killer Cells Showed Potential to Reduce HIV Viral Load in HIV Positive Subjects; Part of HIV Cure Study - Business Wire